Interleukin has executed an agreement to sell the Alan James Group assets of its subsidiary to Pep Products, a subsidiary of Nutraceutical, for approximately $4.6 million.
Lewis Bender, CEO of Interleukin, said: “While the Alan James Group business saw an increase in sales during the last fiscal year and we were able to introduce two new products to the market in the past seven months, this transaction allows us to focus our efforts on growing our core genetic testing business. The sale of AJG provides non-dilutive cash to continue development and promotion of our genetic testing services and products including our new brand of Inherent Health tests.”